Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.48-
QQQ
714.89-
BTC/USD
77843.461.3589%
DIA
525.91-
GLD
398.29-
TLT
80.93-

Vivos Therapeutics Inc

VVOSNASDAQ
Trade with Public
Trade with Public
$0.1840
At close: Sep 14, 5:00 PM EST
$0.1761
-0.0079-4.29%
After Hours: Sep 11, 7:56 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Vivos Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vivos Therapeutics (VVOS).

Price Target Range — 6 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$4Upside to Avg. PT+2097.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 4, 2026Ascendiant CapitalLucas WardPT RaiseBuy$3→$3
Apr 22, 2026Ascendiant CapitalLucas WardPT CutBuy$6→$3
More with Benzinga EdgeGet Access

Analyst Ratings News

CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday

Top Wall Street analysts updated ratings on CRWD, OLLI, XPO, SHAK, UNH, PVH, VVOS, and SYRE. See analyst ratings page for full details.
Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from $3 to $3.1.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $5.5 to $3.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Vivos Therapeutics, Lowers Price Target to $2.5

HC Wainwright & Co. analyst Yi Chen maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $7 to $2.5.
Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $5.5

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $6.5 to $5.5.
Benzinga Newsdesk

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved